UCB (OTCMKTS:UCBJF) Shares Gap Down – Should You Sell?

Shares of UCB SA (OTCMKTS:UCBJF) gapped down prior to trading on Tuesday . The stock had previously closed at $313.72, but opened at $294.11. UCB shares last traded at $310.09, with a volume of 8 shares traded.

Analysts Set New Price Targets

Several research analysts recently commented on UCBJF shares. The Goldman Sachs Group reiterated a “buy” rating on shares of UCB in a research report on Monday, February 16th. Wolfe Research started coverage on UCB in a research report on Monday, February 23rd. They issued an “outperform” rating for the company. Six analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy”.

UCB Stock Down 0.6%

The company has a 50-day simple moving average of $295.29 and a 200-day simple moving average of $298.50. The company has a debt-to-equity ratio of 0.33, a quick ratio of 0.78 and a current ratio of 1.19.

About UCB

UCB SA is a Belgium-based biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe diseases of the immune system and the central nervous system. Founded in 1928 as Union Chimique Belge, the company transitioned from chemicals into pharmaceuticals and biologics and today concentrates its efforts on specialty medicines and research-driven innovation. UCB’s work spans small molecules and biologics, with an emphasis on improving outcomes for patients with chronic and complex conditions.

Key therapeutic areas for UCB include immunology and neurology, where the company markets several well-known products and maintains an active clinical pipeline.